(e.g., tachycardia , labile blood pressure, hyperthermia ), neuromuscular aberrations (e.g., hyperreflexia , incoordination ) and/or gastrointestinal symptoms (e.g., nausea , vomiting , diarrhea ). Withdrawal symptoms have been observed in clinical trials following discontinuation of milnacipran, as with other SNRIs and SSRIs. During marketing of milnacipran, and other SNRIs and SSRIs,